[email protected]

– USA, CO – Bioptix, Inc. (Nasdaq:BIOP), announced that its board of directors has appointed Michael M. Beeghley as chief executive officer effective as of April 6, 2017. Mr. Beeghley succeeds Steve Lundy, who resigned as of April 6, 2017 from his role as president and chief executive officer, and member of the board of directors. Mr. Beeghley will continue in his role as Chairman of the Company’s Board of Directors. Mr. Lundy’s resignation was not the result of any disagreement with the Company.

Michael Beeghley, incoming Chief Executive Officer of Bioptix, stated, “I want to recognize and thank Steve Lundy for all his efforts over the years.” Mr. Beeghley continued, “Bioptix continues to advance on strategic objectives to increase value for its shareholders. This is evidenced by recently announced activities and transactions. We will continue to focus on advancing these initiatives.”

About Bioptix

The Company operates in two separate business segments. As exclusive licensee of the University of Washington in St. Louis the Company focuses on animal healthcare and owns important intellectual property rights related to veterinary products and has granted a license relating to single chain reproductive hormone technology for use in no-human mammals which is under active development by the licensee. The Company is also a diagnostic and testing company which had been involved in developing blood-based testing for diagnosis and treatment of acute appendicitis until a negative response from the FDA in 2014. Since 2016 with the acquisition of Bioptix Diagnostics, Inc. the Company has been seeking commercialization of Enhanced Surface Plasmon Resonance instruments designed to increase the flexibility and reliability of SPR for a broad range of applications. The Company is reviewing possible strategic alternatives for acquisitions. Relative to its diagnostic and instrument business, the Company is exploring alternatives including possible sale, and has adopted a workforce reduction plan after suspending further development of the eSPR technology.

For more information : http://www.bioptix.com

- DisclaimerNews, data and statement included in this release are intended exclusively for information purposes. Product and brand names used in this release maybe trademarks or registered trade marks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.

Talent4Boards Team

here the original post =>

Comments are closed.